CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and
CADx Medical Systems can now market its Second Look CAD product in the U.S., following FDA approval of the system. The subsidiary of Shire Pharmaceuticals Group is preparing to market the product to hospitals, clinics, and mammography centers across the U.S. The decision follows receipt by the company Nov. 21 of an approvable letter from the regulatory agency. Second Look is based on imaging algorithms used by the U.S. military to automatically recognize targets. Approved for both screening and diagnostic use, Second Look will be marketed to radiologists as a tool for highlighting the most critical masses and microcalcifications on mammograms. Clinical trials demonstrated that 26.2% of lesions otherwise missed could be detected with Second Look.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.